| Pharmaceutical Information |
| Drug Name |
Galsulfase |
| Drug ID |
BADD_D01001 |
| Description |
Galsufase is a variant form of the polymorphic human enzyme N-acetylgalactosamine 4-sulfatase of recombinant DNA origin. Galsulfase is a glycoprotein with a molecular weight of approximately 56 kD. The recombinant protein is comprised of 495 amino acids and contains six asparagine-linked glycosylation sites, four of which carry a bis mannose-6-phosphate manose7 oligosaccharide for specific cellular recognition. Post-translational modification of Cys53 produces the catalytic amino acid residue Ca-formylglycine, which is required for enzyme activity and is conserved in all members of the sulfatase enzyme family. |
| Indications and Usage |
For the treatment of adults and children with Mucopolysaccharidosis VI. |
| Marketing Status |
approved; investigational |
| ATC Code |
A16AB08 |
| DrugBank ID |
DB01279
|
| KEGG ID |
D06565
|
| MeSH ID |
C508864
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D05UHF
|
| NDC Product Code |
68135-020 |
| UNII |
59UA429E5G
|
| Synonyms |
galsulfase | Naglazyme |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
552858-79-4 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
